Risk factors

Veradermics is a clinical-stage dermatology company dependent on its lead hair loss product candidate, VDPHL01. The business strategy relies entirely on the cash-pay healthcare market without third-party reimbursement. Intellectual property protection and clinical trial execution drive potential future commercial success.

MeiraGTx continues to accumulate net losses, reaching an accumulated deficit of approximately $816.2 million as of December 31, 2025. The company added new risks covering artificial intelligence adoption, potential biosimilar competition, and environmental liabilities. Clinical and regulatory hurdles for its gene therapy platform and third-party dependencies remain central.

The trust operates without directors, executive officers, or employees, relying entirely on a corporate trustee and information from working interest owners.

The company abandoned its metaverse strategy and spin-off plans for Habytat, dropping risks 23 and 46. Competition was expanded to include TikTok, Pinterest, Amazon Drive, and others. Financial figures were updated for 2025 showing a net loss of $3,040,119.

Nakamoto Inc. transitioned from healthcare operations to a Bitcoin treasury company, bringing new volatility and regulatory risks.

Accumulated deficit reached $1,184.1 million as clinical-stage development continues without approved products. The company addressed Nasdaq minimum bid price compliance issues in 2025. Exposure to the enacted BIOSECURE Act threatens foreign manufacturing and vendor relationships.

OneIM Acquisition Corp. is a blank check company searching for an initial business combination within 24 to 27 months.

Pelareorep remains an unapproved clinical-stage candidate, with trial design, safety, efficacy, and regulatory approval dominating risk.

Customer concentration is sharper: two customers generated 55% and 11% of 2025 revenue, while one held 73% of accounts receivable.

Going concern doubt persists with net losses dropping to $2.8 million in 2025 and accumulated deficit reaching $104.4 million. Stock volatility and litigation threats remain standard risk factors.

The company removed specific disclosure regarding income volatility from its Jet.AI investment and counterparty credit risks.

This SPAC risk section is dominated by risks of failing to complete a business combination within 24 months, high redemptions, and lack of target information. It highlights vulnerabilities around potential complex cross-border targets, debt or equity financing hurdles, and evolving SEC and Cayman Islands regulations.